Ionis has teamed up with AstraZeneta to develop a new drug 4 to be used to treat NASH

ION455 is the fourth drug that Ionis has developed in partnership with AstraZeneta, after Ionis and AstraZeneta worked together on potential treatments for kidney disease, cardiovascular disease and cancer, and ION455 is the first drug that Ionis has developed in partnership with AstraZeneta. Two potential drugs for NASH, the other is ION839 (AZD2693), an antonym oligonucleotide designed to inhibit the production of Patatin-like phospholipidase protein 3 (PNPLA3).
addition, Ionis is independently developing another NASH drug, ION224, which is one of more than 20 drugs the company is prioritizing and preparing for commercialization, with antonys designed to inhibit the production of diamic glycerin O-yl transferase 2 (DGAT2).
NASH is a chronic, aggressive liver disease characterized by fat build-up and inflammation in the liver, which can lead to scar formation or fibrosis and impair liver function.
NASH patients with advanced liver disease (including liver loss of function and liver cancer) were higher than in the general population.
, no drug therapies have been approved worldwide for NASH treatment, and patient treatment options are very limited.
source: Instant Medicine